| EBV genes |
BKRF1 |
BYRF1 |
BLF-BERF (1, 2, 3/4) |
BNLF1 |
BNLF2 |
BCRF1 |
| EBV-protein |
EBNA-1 |
EBNA-2 |
EBNA-3 (A,B,C) |
LMP-1 |
LMP-2 (A,B) |
Not translated EBER-1,2 |
| Immunogenic properties * |
-/+ |
+ |
++ |
-/+ |
-/+ |
- |
| EBV infection phase |
Lytic phase ** |
+ |
+ |
+ |
- |
- |
- |
| Latency phase |
+ |
-/+ |
-/+ |
-/+ |
-/+ |
+ |
| EBV latency patterns |
Type 1 (Burkitt's lymphoma) |
+ |
- |
- |
- |
- |
+ |
| Type 2 (nasopharyngeal carcinoma, Hodgkin's lymphoma and NK/T-cell neoplasms) |
+ |
- |
- |
+ |
+ |
+ |
| Type 3 (Infectious mononucleosis, AIDS associated lymphomas, post-transplant B-cell LPD) |
+ |
+ |
+ |
+ |
+ |
+ |
| Others (healthy carriers) |
+ |
- |
- |
- |
+ |
+ |
AIDS: Acquired Immunodeficiency Syndrome; CTL: Cytotoxic T Cells; EBV: Epstein Barr virus; EBNA: EBV Nuclear Antigens; LMP: EBV Latent Membrane Proteins; EBER:
Early Region Epstein Barr Virus RNA; LPD: Lympho Proliferative Disorder; NFκB: Nuclear Factor kappa B; TNFR: Tumor Necrosis Factor Receptor; PKC: Protein Kinase C.
* Immunogenic properties for the generation of cytotoxic T cells;
** Other EBV antigens expressed during the lytic phase are the EBV-EA (early antigens), the EBV-MA
(membrane antigen), the EBV-VCA (viral capsid antigen) and the EBV-AN (alkaline nuclease) |
